Lewis-Carey Mary Beth, Kee Stephen T
University of New Mexico, Albuquerque, NM 87131-5336, USA.
Tech Vasc Interv Radiol. 2003 Jun;6(2):103-6. doi: 10.1053/tvir.2003.36444.
As of July 2000, there were 4 closure devices with Food and Drug Administration (FDA) approval. The devices are successfully deployed in 89% to 98% of cases, and the complication rates are comparable to those seen with manual compression. Minor access site complications are defined as bleeding not requiring transfusion or surgical repair, hematoma (<5 cm), and pain at the puncture site. Major complications include hematoma (>5 cm), bleeding at the site requiring transfusion, pseudoaneurysm, arteriovenous fistula, retroperitoneal hemorrhage, plug embolization, groin infection, and death.
截至2000年7月，有4种封堵装置获得了美国食品药品监督管理局（FDA）的批准。这些装置在89%至98%的病例中成功植入，并发症发生率与手动压迫相当。轻微的穿刺部位并发症定义为无需输血或手术修复的出血、血肿（<5厘米）以及穿刺部位疼痛。主要并发症包括血肿（>5厘米）、需要输血的部位出血、假性动脉瘤、动静脉瘘、腹膜后出血、封堵器栓塞、腹股沟感染和死亡。
